AVENUE THERAPEUTICS, INC. (ATXI): Nasdaq/NYSE listing notice — Nasdaq to delist Avenue Therapeutics on March 19; stock to trade on OTC Markets

AVENUE THERAPEUTICS, INC.

Nasdaq notified Company it will delist common stock effective at open on March 19, 2025.
Delisting due to failure to maintain minimum $2.5M stockholders' equity per Nasdaq Rule 5550(b)(1).
Company failed to meet conditions of Panel exception requiring disclosure of equity-increasing transactions by March 14.
Common stock (ATXI) expected to begin trading on OTC Markets on March 19, 2025.
Company will continue filing periodic reports with SEC but warns of uncertain trading liquidity.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

AVENUE THERAPEUTICS, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

March 17, 2025, The Nasdaq Stock Market LLC (“Nasdaq”) notified Avenue Therapeutics, Inc. (the “Company”) that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s common stock and that trading of the Company’s common stock will be suspended at the open of trading on March 19, 2025. As previously reported, the Company was in violation of Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000. Also as previously reported, on November 26, 2024, the Company received a delist let

View on SEC.gov

Browse all listing & compliance notices →

AVENUE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-25-024505

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.